GSK-104730

Study Sponsor: GSK

Study Title

A phase III, multicentre booster vaccination study to assess the immunogenicity, safety and reactogenicity of a dose of Mencevax™ ACWY at 24 to 30 months of age in subjects primed with an investigational vaccination regimen in study 100480 and boosted at 15 to 24 months of age in study 104727.

Medicine or Vaccine (generic name)

Meningococcal Serogroups A, C, W-135 and Y Vaccine

Sponsor Identification Number

104730

Trial Registry Identification Number(#'s)

NCT00136604

Medical Condition

Infections, Meningococcal

Phase

Phase 3

Link to GSK Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=104730

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00136604

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to 100480 and 104727. An annotated case report form is not available for this study. A blank case report form will be provided. The results of this study 104730 are summarised with studies 104727 and 100480 on the GSK Study Register.

Date Added to this Site

October 2014